{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T20:40:07Z","timestamp":1745786407925,"version":"3.40.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02424-3","type":"journal-article","created":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T20:11:20Z","timestamp":1745784680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Laparoscopic curative resection following perioperative chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel and its influence on Claudin18.2 expression in advanced gastric or gastroesophageal junction adenocarcinoma: a two-case report"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1130-0549","authenticated-orcid":false,"given":"Tohru","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9136-1818","authenticated-orcid":false,"given":"Takahiro","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Maejima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Aimono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Fukahori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1068-7024","authenticated-orcid":false,"given":"Yusuke","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,27]]},"reference":[{"issue":"3","key":"2424_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2424_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320. https:\/\/doi.org\/10.1056\/NEJMoa055531.","journal-title":"N Engl J Med"},{"issue":"10184","key":"2424_CR3","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1.","journal-title":"Lancet"},{"issue":"6","key":"2424_CR4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/bjs.9484","volume":"101","author":"A Tsuburaya","year":"2014","unstructured":"Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101(6):653\u201360. https:\/\/doi.org\/10.1002\/bjs.9484.","journal-title":"Br J Surg"},{"issue":"2","key":"2424_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10120-019-01007-w","volume":"23","author":"D Takahari","year":"2020","unstructured":"Takahari D, Ito S, Mizusawa J, Katayama H, Terashima M, Sasako M, et al. Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002). Gastric Cancer. 2020;23(2):293\u20139. https:\/\/doi.org\/10.1007\/s10120-019-01007-w.","journal-title":"Gastric Cancer"},{"issue":"2","key":"2424_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s10120-020-01136-7","volume":"24","author":"Y Iwasaki","year":"2021","unstructured":"Iwasaki Y, Terashima M, Mizusawa J, Katayama H, Nakamura K, Katai H, et al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer. 2021;24(2):492\u2013502. https:\/\/doi.org\/10.1007\/s10120-020-01136-7.","journal-title":"Gastric Cancer"},{"issue":"32","key":"2424_CR7","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.22.00380","volume":"40","author":"RD Hofheinz","year":"2022","unstructured":"Hofheinz RD, Merx K, Haag GM, Springfeld C, Ettrich T, Borchert K, et al. FLOT versus FLOT\/Trastuzumab\/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA study group. J Clin Oncol. 2022;40(32):3750\u201361. https:\/\/doi.org\/10.1200\/JCO.22.00380.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2424_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1200\/JCO.23.00975","volume":"42","author":"S Lorenzen","year":"2024","unstructured":"Lorenzen S, G\u00f6tze TO, Thuss-Patience P, Biebl M, Homann N, Schenk M, et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 Trial. J Clin Oncol. 2024;42(4):410\u201320. https:\/\/doi.org\/10.1200\/JCO.23.00975.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2424_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/ijc.34495","volume":"153","author":"TO Goetze","year":"2023","unstructured":"Goetze TO, Hofheinz RD, Gaiser T, Schmalenberg H, Strumberg D, Goekkurt E, et al. Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: a randomized phase II\/III trial of the German AIO and Italian GOIM. Int J Cancer. 2023;153(1):153\u201363. https:\/\/doi.org\/10.1002\/ijc.34495.","journal-title":"Int J Cancer"},{"issue":"2","key":"2424_CR10","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s10120-023-01453-7","volume":"27","author":"Y Kurokawa","year":"2024","unstructured":"Kurokawa Y, Doki Y, Kitabayashi R, Yoshikawa T, Nomura T, Tsuji K, et al. Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704). Gastric Cancer. 2024;27(2):366\u201374. https:\/\/doi.org\/10.1007\/s10120-023-01453-7.","journal-title":"Gastric Cancer"},{"issue":"2","key":"2424_CR11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/jjco\/hyad149","volume":"54","author":"R Kita","year":"2024","unstructured":"Kita R, Yanagimoto Y, Imazeki H, Booka E, Tsushima T, Mizusawa J, et al. Protocol digest of a randomized controlled adaptive Phase II\/III trial of neoadjuvant chemotherapy for Japanese patients with oesophagogastric junction adenocarcinoma: Japan Clinical Oncology Group Study JCOG2203 (NEO-JPEG). Jpn J Clin Oncol. 2024;54(2):206\u201311. https:\/\/doi.org\/10.1093\/jjco\/hyad149.","journal-title":"Jpn J Clin Oncol"},{"issue":"32","key":"2424_CR12","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.2217\/fon-2023-0605","volume":"19","author":"T Hashimoto","year":"2023","unstructured":"Hashimoto T, Nakayama I, Ohashi M, Mizusawa J, Kawachi H, Kita R, et al. Randomized phase II study comparing neoadjuvant 5-fluorouracil\/oxaliplatin\/docetaxel versus docetaxel\/oxaliplatin\/S-1 for patients with type 4 or large type 3 gastric cancer. Future Oncol. 2023;19(32):2147\u201355. https:\/\/doi.org\/10.2217\/fon-2023-0605.","journal-title":"Future Oncol"},{"issue":"6","key":"2424_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.4103\/1735-5362.359430","volume":"17","author":"P Farrokhi","year":"2022","unstructured":"Farrokhi P, Sadeghi A, Sharifi M, Riechelmann R, Moghaddas A. Efficacy and safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as perioperative chemotherapy treatments for resectable gastric cancer patients; a report from the middle east. Res Pharm Sci. 2022;17(6):621\u201334. https:\/\/doi.org\/10.4103\/1735-5362.359430.","journal-title":"Res Pharm Sci"},{"issue":"1","key":"2424_CR14","doi-asserted-by":"publisher","first-page":"6093","DOI":"10.1038\/s41467-020-19965-6","volume":"11","author":"BK Sah","year":"2020","unstructured":"Sah BK, Zhang B, Zhang H, Li J, Yuan F, Ma T, et al. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun. 2020;11(1):6093. https:\/\/doi.org\/10.1038\/s41467-020-19965-6.","journal-title":"Nat Commun"},{"issue":"10","key":"2424_CR15","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/j.ejso.2019.06.010","volume":"45","author":"J Cheng","year":"2019","unstructured":"Cheng J, Cai M, Shuai X, Gao J, Wang G, Tao K. Multimodal treatments for resectable gastric cancer: a systematic review and network meta-analysis. Eur J Surg Oncol. 2019;45(10):1796\u2013805. https:\/\/doi.org\/10.1016\/j.ejso.2019.06.010.","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"2424_CR16","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1007\/s10120-022-01314-9","volume":"25","author":"G Grizzi","year":"2022","unstructured":"Grizzi G, Petrelli F, Di Bartolomeo M, Viti M, Texeira Moraes M, Luciani A, et al. Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis. Gastric Cancer. 2022;25(5):982\u20137. https:\/\/doi.org\/10.1007\/s10120-022-01314-9.","journal-title":"Gastric Cancer"},{"key":"2424_CR17","doi-asserted-by":"publisher","first-page":"175883591983896","DOI":"10.1177\/1758835919838963","volume":"11","author":"J Cheng","year":"2019","unstructured":"Cheng J, Cai M, Shuai X, Gao J, Wang G, Tao K. Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis. Ther Adv Med Oncol. 2019;11:1758835919838963. https:\/\/doi.org\/10.1177\/1758835919838963.","journal-title":"Ther Adv Med Oncol"},{"key":"2424_CR18","doi-asserted-by":"publisher","unstructured":"Hoeppner J, Brunner T, Lordick F, Schmoor C, Kulemann B, Neumann UP, et al. Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial). J Clin Oncol. 2024;42(17_suppl):LBA1\u2013LBA. https:\/\/doi.org\/10.1200\/JCO.2024.42.17_suppl.LBA1","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1"},{"key":"2424_CR19","doi-asserted-by":"publisher","unstructured":"Wang C, Wang Y, Chen J, Wang Y, Pang C, Liang C, et al. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer. BMC Gastroenterol. 2023;23(1):283. https:\/\/doi.org\/10.1186\/s12876-023-02924-y","DOI":"10.1186\/s12876-023-02924-y"},{"key":"2424_CR20","doi-asserted-by":"publisher","unstructured":"Angerilli V, Ghelardi F, Nappo F, Grillo F, Parente P, Lonardi S, et al. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: a literature review with expert opinion. Pathol Res Pract. 2024;254:155145. https:\/\/doi.org\/10.1016\/j.prp.2024.155145","DOI":"10.1016\/j.prp.2024.155145"},{"key":"2424_CR21","doi-asserted-by":"publisher","unstructured":"Nishibata T, Weng J, Omori K, Sato Y, Nakazawa T, Suzuki T, et al. Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models. J Pharmacol Sci. 2024;155(3):84\u201393. https:\/\/doi.org\/10.1016\/j.jphs.2024.04.004","DOI":"10.1016\/j.jphs.2024.04.004"},{"key":"2424_CR22","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2147\/CMAR.S200883","volume":"11","author":"K Wang","year":"2019","unstructured":"Wang K, Ren Y, Ma Z, Li F, Cheng X, Xiao J, et al. Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) as preoperative and postoperative chemotherapy compared with surgery followed by chemotherapy for patients with locally advanced gastric cancer: a propensity score-based analysis. Cancer Manag Res. 2019;11:3009\u201320. https:\/\/doi.org\/10.2147\/CMAR.S200883.","journal-title":"Cancer Manag Res"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02424-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02424-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02424-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T20:11:20Z","timestamp":1745784680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02424-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,27]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2424"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02424-3","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,27]]},"assertion":[{"value":"26 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Tokushukai Group Ethics Committee (Aug 29, 2024\/No: TGE02602-012).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent to participate and to publish was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"623"}}